TPIV200/huFR-1: Phase II started

TapImmune and AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) began an open-label, U.S. Phase

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE